Nobel Prize winner Shimon Sakaguchi, a pioneer in regulatory T cell (Treg) biology, discusses the path from early observations to reprogrammed cell therapies for autoimmune disease.

Read more here

Previous
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Next
Kincell Bio Partners with RegCell to Advance Treg Cell Therapy Toward Clinical Trials